U.S. markets closed

Genscript Biotech Corporation (GNNSF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.15000.0000 (0.00%)
At close: 10:23AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.1500
Open4.1500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.1500 - 4.1500
52 Week Range1.3000 - 5.3000
Volume1,000
Avg. Volume576
Market Cap8.903B
Beta (5Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)-0.0940
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 05, 2017
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GENSCRIPT BIOTECH CORPORATION
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our latest coronavirus update; the hotel industry's potential to return to normal; post-sell-off software stocks; and notes from new coverage GenScript, Howmet Aerospace, and Manhattan Associates.
    Rating
    Fair Value
    Economic Moat
    last yearMorningstar
View more
  • PR Newswire

    GenScript Biotech Reports First Half 2021 Results

    GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and manufacture, today reported its first half 2021 financial results for the six months ended June 30. It also announced that the Group has expanded its presence in the gene and cell therapy (GCT) industry, with aggressive investments from the Group's life science services and products business, biologics CDMO business, and cell therapy business.

  • PR Newswire

    Genscript Biotech Reports 2021 Interim Financial Results

    Genscript Biotech (HKEX: 1548.HK) (GenScript), a global leading biotech company, today announced its audited financial results for the year ended June 30, 2021.

  • PR Newswire

    GenScript Joins Forces with Allozymes by Providing Smart Libraries Construction for Precision Protein Engineering

    GenScript Biotech Corporation (Stock Code: 1548.HK) today announced a collaboration with Allozymes, a synthetic biology company transforming ingredient manufacturing by unlocking protein engineering potential through groundbreaking technologies. In this partnership, GenScript will provide the mutant libraries construction to Allozymes for their downstream applications across various industries including pharmaceuticals, cosmetics and food & beverage.